AstraZeneca (Netherlands)

Recent papers from AstraZeneca (Netherlands)

1. Discovery of Nivegacetor, an Advanced γ-Secretase Modulator, for the Treatment of Alzheimer’s DiseaseJournal of Medicinal Chemistry · 2026
2. Clinical outcome predicted by coronary flow reserve in patients with a prior myocardial infarctionEuropean Heart Journal · 2026
3. A First-Generation Integrated Continuous Bioprocessing Facility: Conceptual Design and Economic AnalysisPDA Journal of Pharmaceutical Science and Technology · 2026
4. Tumor and ctDNA concordance of actionable alterations in metastatic breast cancernpj Breast Cancer · 2026
5. Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditionsBritish Journal of Clinical Pharmacology · 2026
6. Rapid Alternating Polarity‐Enabled Electrochemical Decarboxylative Borylation of Aryl Carboxylic AcidsChemElectroChem · 2026
7. From Phase Ib/ II to Seamless Phase II / III : A Simulation‐Based Discussion of Design Strategies for Dose Optimization and Confirmatory PhaseClinical Pharmacology & Therapeutics · 2026
8. Patient Characteristics and Clinical Indicators Influencing Oncologists’ Perceptions of Prognosis in Ovarian Cancer: A Discrete Choice ExperimentInternational Journal of Gynecological Cancer · 2026
9. Safety and efficacy of ceralasertib, an ATR kinase inhibitor, combined with olaparib: dose escalation in advanced solid tumours and dose expansion in advanced breast cancerBritish Journal of Cancer · 2026
10. Myeloid-derived suppressor cells in hematologic malignancies: A current state of the fieldThe Journal of Immunology · 2026
11. Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH studyClinical Cancer Research · 2026
12. The Batch Nature of Continuous Flow Production via Natural-Abundance Stable IsotopesOrganic Process Research & Development · 2026
13. Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐ DXd ), a TROP2 ‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung CancerClinical Pharmacology & Therapeutics · 2026
14. From Compliance to Strategic Partner: The Transformation of Regulatory Affairs in AstraZeneca Local AffiliatesPharmaceutical Medicine · 2026
15. Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trialClinical and Translational Science · 2022
16. Factors influencing oncologists’ decisions for germline BRCA testing and adjuvant therapy selection in HER2-negative early breast cancerFrontiers in Oncology · 2026
17. How to be SMART in oncology: A practical framework to assess the contribution of phase using sequential multiple adaptive randomized treatment designsClinical Trials · 2026
18. Natural language processing-based model to predict radiation pneumonitis in patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy: a retrospective cohort studyEClinicalMedicine · 2026
19. Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trialThe Lancet · 2026
20. Packing, Flow and Aerosolization Properties of Binary Adhesive Mixtures Containing Micronized and Spray-Dried DrugsPharmaceutics · 2026